A detailed history of State Street Corp transactions in Alpine Immune Sciences, Inc. stock. As of the latest transaction made, State Street Corp holds 2,845,839 shares of ALPN stock, worth $0. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,845,839
Previous 1,390,029 104.73%
Holding current value
$0
Previous $26.5 Million 325.81%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$17.75 - $41.6 $25.8 Million - $60.6 Million
1,455,810 Added 104.73%
2,845,839 $113 Million
Q4 2023

Feb 14, 2024

BUY
$8.54 - $20.22 $6.7 Million - $15.9 Million
784,484 Added 129.55%
1,390,029 $26.5 Million
Q3 2023

Nov 14, 2023

BUY
$10.13 - $13.98 $331,281 - $457,187
32,703 Added 5.71%
605,545 $6.93 Million
Q2 2023

Aug 14, 2023

BUY
$6.84 - $11.91 $1.55 Million - $2.69 Million
226,171 Added 65.24%
572,842 $5.89 Million
Q1 2023

May 15, 2023

BUY
$7.0 - $8.75 $302,771 - $378,463
43,253 Added 14.26%
346,671 $2.68 Million
Q4 2022

Feb 14, 2023

BUY
$5.45 - $7.35 $133,176 - $179,604
24,436 Added 8.76%
303,418 $2.23 Million
Q3 2022

Nov 15, 2022

BUY
$6.89 - $9.39 $75,101 - $102,351
10,900 Added 4.07%
278,982 $2.01 Million
Q2 2022

Aug 15, 2022

BUY
$6.71 - $9.52 $318,463 - $451,828
47,461 Added 21.51%
268,082 $2.28 Million
Q1 2022

May 16, 2022

BUY
$6.41 - $13.89 $93,643 - $202,919
14,609 Added 7.09%
220,621 $1.98 Million
Q4 2021

Feb 14, 2022

BUY
$10.41 - $13.95 $85,528 - $114,613
8,216 Added 4.15%
206,012 $2.85 Million
Q3 2021

Nov 15, 2021

BUY
$8.19 - $11.31 $202,104 - $279,096
24,677 Added 14.25%
197,796 $2.11 Million
Q2 2021

Aug 16, 2021

BUY
$8.81 - $15.03 $1.53 Million - $2.6 Million
173,119 New
173,119 $1.56 Million

Others Institutions Holding ALPN

About ALPINE IMMUNE SCIENCES, INC.


  • Ticker ALPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,006,700
  • Description
  • Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...
More about ALPN
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.